- $92.42m
- $49.24m
- $7.95m
Coya rises after US FDA nod for ALS therapy mid-stage trial
Coya rises after US FDA nod for ALS therapy mid-stage trial
Brief: Coya Therapeutics Announces FDA Acceptance Of Investigational New Drug (IND) Application
Brief: Coya Therapeutics Inc - FDA Unable To Meet Review Goal Date For Coya's Ind For Phase 2 Als Study - SEC Filing
Brief: Coya Therapeutics Inc - Re-Submits Ind Application To FDA Related To Phase 2 Study Of Coya 302 For Als Treatment - SEC Filing
Brief: Coya Therapeutics Announces Issuance Of New U.S. Patent Protecting Methods Of Producing Recombinant Human (Rh) Interleukin-2 (Aldesleukin) Liquid Formulations
Brief: Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia
Brief: Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program
Brief: Coya Therapeutics Inc Reports Significant Improvement In Inflammatory Markers In Alzheimer's Patients
Brief: Coya Therapeutics Inc Files For Resale Of Up To 1.4 Million Shares By The Selling Stockholders - SEC Filing
Brief: Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role As Chief Executive Officer
Coya rises as Alzheimer's drug meets safety and shows immune response in trial
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial
Brief: Coya Therapeutics Announces $10.0 Million Private Placement
Brief: Coya Therapeutics Names Arun Swaminathan As CEO
Brief: Coya Therapeutics Reports Unaudited Second Quarter 2024 Results
Brief: Coya Therapeutics Inc Files For Shelf Of Up To 603,136 Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Brief: Coya Therapeutics Announces $5 Million Strategic Investment